S&P 500   3,157.10 (+0.49%)
DOW   28,040.91 (+0.46%)
QQQ   205.82 (+0.41%)
AAPL   269.73 (-0.38%)
FB   200.84 (-0.70%)
MSFT   152.01 (+0.20%)
GOOGL   1,343.50 (-0.06%)
AMZN   1,753.69 (+0.28%)
CGC   21.02 (+3.80%)
NVDA   221.47 (+1.90%)
MU   50.70 (+2.92%)
BABA   203.87 (-0.38%)
TSLA   359.68 (+1.98%)
AMD   41.30 (+4.64%)
ACB   2.59 (+5.71%)
F   9.29 (+1.98%)
PRI   136.53 (+0.80%)
NFLX   296.19 (-0.92%)
BAC   34.38 (+2.20%)
GILD   67.53 (-0.37%)
DIS   147.59 (+0.00%)
S&P 500   3,157.10 (+0.49%)
DOW   28,040.91 (+0.46%)
QQQ   205.82 (+0.41%)
AAPL   269.73 (-0.38%)
FB   200.84 (-0.70%)
MSFT   152.01 (+0.20%)
GOOGL   1,343.50 (-0.06%)
AMZN   1,753.69 (+0.28%)
CGC   21.02 (+3.80%)
NVDA   221.47 (+1.90%)
MU   50.70 (+2.92%)
BABA   203.87 (-0.38%)
TSLA   359.68 (+1.98%)
AMD   41.30 (+4.64%)
ACB   2.59 (+5.71%)
F   9.29 (+1.98%)
PRI   136.53 (+0.80%)
NFLX   296.19 (-0.92%)
BAC   34.38 (+2.20%)
GILD   67.53 (-0.37%)
DIS   147.59 (+0.00%)
S&P 500   3,157.10 (+0.49%)
DOW   28,040.91 (+0.46%)
QQQ   205.82 (+0.41%)
AAPL   269.73 (-0.38%)
FB   200.84 (-0.70%)
MSFT   152.01 (+0.20%)
GOOGL   1,343.50 (-0.06%)
AMZN   1,753.69 (+0.28%)
CGC   21.02 (+3.80%)
NVDA   221.47 (+1.90%)
MU   50.70 (+2.92%)
BABA   203.87 (-0.38%)
TSLA   359.68 (+1.98%)
AMD   41.30 (+4.64%)
ACB   2.59 (+5.71%)
F   9.29 (+1.98%)
PRI   136.53 (+0.80%)
NFLX   296.19 (-0.92%)
BAC   34.38 (+2.20%)
GILD   67.53 (-0.37%)
DIS   147.59 (+0.00%)
S&P 500   3,157.10 (+0.49%)
DOW   28,040.91 (+0.46%)
QQQ   205.82 (+0.41%)
AAPL   269.73 (-0.38%)
FB   200.84 (-0.70%)
MSFT   152.01 (+0.20%)
GOOGL   1,343.50 (-0.06%)
AMZN   1,753.69 (+0.28%)
CGC   21.02 (+3.80%)
NVDA   221.47 (+1.90%)
MU   50.70 (+2.92%)
BABA   203.87 (-0.38%)
TSLA   359.68 (+1.98%)
AMD   41.30 (+4.64%)
ACB   2.59 (+5.71%)
F   9.29 (+1.98%)
PRI   136.53 (+0.80%)
NFLX   296.19 (-0.92%)
BAC   34.38 (+2.20%)
GILD   67.53 (-0.37%)
DIS   147.59 (+0.00%)
Log in

NASDAQ:NXTC - NextCure Stock Price, Forecast & News

$50.34
-1.21 (-2.35 %)
(As of 12/12/2019 02:08 PM ET)
Today's Range
$49.71
Now: $50.34
$52.38
50-Day Range
$25.43
MA: $42.43
$82.89
52-Week Range
$13.86
Now: $50.34
$109.00
Volume132,489 shs
Average Volume588,728 shs
Market Capitalization$1.15 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
There is no company description available for NextCure Inc.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NXTC
CUSIPN/A
CIKN/A
Phone240-399-4900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-22,800,000.00

Miscellaneous

EmployeesN/A
Market Cap$1.15 billion
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable

Receive NXTC News and Ratings via Email

Sign-up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.


NextCure (NASDAQ:NXTC) Frequently Asked Questions

What is NextCure's stock symbol?

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

How were NextCure's earnings last quarter?

NextCure Inc (NASDAQ:NXTC) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.02. The firm earned $1.58 million during the quarter, compared to the consensus estimate of $1.50 million. View NextCure's Earnings History.

When is NextCure's next earnings date?

NextCure is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for NextCure.

What price target have analysts set for NXTC?

5 equities research analysts have issued 12 month target prices for NextCure's shares. Their forecasts range from $44.00 to $87.00. On average, they anticipate NextCure's stock price to reach $63.20 in the next twelve months. This suggests a possible upside of 25.5% from the stock's current price. View Analyst Price Targets for NextCure.

What is the consensus analysts' recommendation for NextCure?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NextCure.

Has NextCure been receiving favorable news coverage?

News articles about NXTC stock have trended very negative recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NextCure earned a coverage optimism score of -3.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for NextCure.

Are investors shorting NextCure?

NextCure saw a decrease in short interest in the month of November. As of November 29th, there was short interest totalling 506,800 shares, a decrease of 19.0% from the November 14th total of 625,500 shares. Based on an average trading volume of 477,000 shares, the short-interest ratio is currently 1.1 days. Approximately 4.1% of the shares of the company are sold short. View NextCure's Current Options Chain.

Who are some of NextCure's key competitors?

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include Alibaba Group (BABA), Home Depot (HD), Honeywell International (HON), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), NVIDIA (NVDA), CVS Health (CVS), Mcdonald's (MCD), Amgen (AMGN) and Johnson & Johnson (JNJ).

When did NextCure IPO?

(NXTC) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

When did NextCure's lock-up period expire?

NextCure's lock-up period expired on Tuesday, November 5th. NextCure had issued 5,000,000 shares in its IPO on May 9th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

Who are NextCure's major shareholders?

NextCure's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Matthews International Capital Management LLC (1.84%), State Street Corp (0.24%), Squarepoint Ops LLC (0.11%), Strs Ohio (0.03%) and Barclays PLC (0.01%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View Institutional Ownership Trends for NextCure.

Which institutional investors are selling NextCure stock?

NXTC stock was sold by a variety of institutional investors in the last quarter, including Matthews International Capital Management LLC and Barclays PLC. View Insider Buying and Selling for NextCure.

Which institutional investors are buying NextCure stock?

NXTC stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Squarepoint Ops LLC and Strs Ohio. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View Insider Buying and Selling for NextCure.

How do I buy shares of NextCure?

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NextCure's stock price today?

One share of NXTC stock can currently be purchased for approximately $50.34.

How big of a company is NextCure?

NextCure has a market capitalization of $1.15 billion. View Additional Information About NextCure.

What is NextCure's official website?

The official website for NextCure is http://www.nextcure.com/.

How can I contact NextCure?

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]


MarketBeat Community Rating for NextCure (NASDAQ NXTC)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  32 (Vote Outperform)
Underperform Votes:  22 (Vote Underperform)
Total Votes:  54
MarketBeat's community ratings are surveys of what our community members think about NextCure and other stocks. Vote "Outperform" if you believe NXTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Featured Article: How mutual funds make money

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel